Sarcomas | Specialty

10-Year Trabectedin Real-World Data Demonstrate Efficacy in Sarcoma

July 26th 2017

Long-term follow-up showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high grade soft tissue sarcomas.

Cediranib Reduces Tumor Burden in Sarcoma

July 21st 2017

Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

July 19th 2017

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

Dr. Somaiah on NY-ESO-1 Expression in Soft Tissue Sarcoma

July 7th 2017

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the expression of NY-ESO-1 in patients with soft tissue sarcoma.

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

June 23rd 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma

June 23rd 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

Aldoxorubicin Improves PFS in Advanced Soft Tissue Sarcoma

June 23rd 2017

Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.

Dr. Wilky on Determining Treatments for Sarcoma

June 23rd 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses how to determine which treatment a patient with sarcoma should receive.

FDA Grants Orphan Drug Status to Tazemetostat for Soft Tissue Sarcoma

June 22nd 2017

Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.

Nivolumab/Ipilimumab Combo Active in Sarcoma

June 21st 2017

Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate of 16% in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial.

Dr. Somaiah on CMB305 in Soft Tissue Sarcoma

June 19th 2017

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses phase I findings of CMB305 in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.

test-1

June 17th 2017

Efficacy of Pembrolizumab in Multiple Subtypes of Sarcoma

June 16th 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses a clinical trial exploring the PD-1 inhibitor pembrolizumab (Keytruda) in multiple subtypes of sarcoma.

Dr. Grignani on the Future of Treatments for Sarcoma

June 8th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Dr. Catton on Quality Assurance for Radiation Therapy for Sarcoma

May 19th 2017

Charles Catton, MD, professor, Department of Radiation Oncology University of Toronto, discusses quality assurance with radiation therapy for patients with sarcoma.

Adjuvant Radiotherapy Improves Survival in Rare Sarcoma Subtype

May 19th 2017

Adjuvant radiotherapy was associated with improved survival for patients with non-retroperitoneal abdominal soft tissue sarcomas (NRA-STS), but the addition of chemotherapy did not confer a similar survival benefit.

Chemoradiation and Radiation Produced Similar Outcomes in Extremity Soft Tissue Sarcoma

May 18th 2017

Researchers at Istanbul University Institute of Oncology have concluded that patients with high-risk extremity soft tissue sarcoma have similar 3-year outcomes whether they are assigned to neoadjuvant sequential chemoradiotherapy or radiation alone.

Dr. Kasper on Future Treatment Approaches in Sarcoma

May 17th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses future treatment approaches in the field of sarcoma and the potential role of imatinib (Gleevac).

Doxorubicin/Ifosfamide Combo for Sarcoma Most Effective in Select Population

May 15th 2017

Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.

Apatinib Shows Potential in Advanced Sarcoma

May 11th 2017

Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.